- Home
- SAVA vs AVTX Comparison
SAVA vs AVTX Comparison
Compare SAVA & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- AVTX
- Stock Information
- Founded
- SAVA 1998
- AVTX 2011
- Country
- SAVA United States
- AVTX United States
- Employees
- SAVA N/A
- AVTX N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- SAVA Health Care
- AVTX Health Care
- Exchange
- SAVA Nasdaq
- AVTX Nasdaq
- Market Cap
- SAVA 70.5M
- AVTX 57.4M
- IPO Year
- SAVA N/A
- AVTX 2015
- Fundamental
- Price
- SAVA $1.99
- AVTX $4.84
- Analyst Decision
- SAVA Buy
- AVTX Strong Buy
- Analyst Count
- SAVA 3
- AVTX 7
- Target Price
- SAVA $54.50
- AVTX $31.00
- AVG Volume (30 Days)
- SAVA 1.1M
- AVTX 97.2K
- Earning Date
- SAVA 08-07-2025
- AVTX 08-11-2025
- Dividend Yield
- SAVA N/A
- AVTX N/A
- EPS Growth
- SAVA N/A
- AVTX N/A
- EPS
- SAVA N/A
- AVTX N/A
- Revenue
- SAVA N/A
- AVTX $441,000.00
- Revenue This Year
- SAVA N/A
- AVTX N/A
- Revenue Next Year
- SAVA N/A
- AVTX N/A
- P/E Ratio
- SAVA N/A
- AVTX N/A
- Revenue Growth
- SAVA N/A
- AVTX N/A
- 52 Week Low
- SAVA $1.15
- AVTX $3.39
- 52 Week High
- SAVA $42.20
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- SAVA 51.90
- AVTX 54.83
- Support Level
- SAVA $1.76
- AVTX $4.50
- Resistance Level
- SAVA $2.17
- AVTX $5.05
- Average True Range (ATR)
- SAVA 0.10
- AVTX 0.30
- MACD
- SAVA -0.02
- AVTX 0.02
- Stochastic Oscillator
- SAVA 55.95
- AVTX 63.66
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).